Toward a commercial synthesis of (+)-discodermolide.
In this review some of the criteria required for a viable chemical (+)-discodermolide production process are discussed by critical evaluation of the available literature approaches. A further route involving the use of polyketide synthase to produce (+)-discodermolide fragments by fermentation is also described. Both approaches have advantages and disadvantages and require significant optimization in order to achieve commercialization of this important natural product.
Mickel
Stuart J
SJ
Novartis Pharma AG, Chemical and Analytical Development, CH 4002 Basel, Switzerland. stuart_john.mickel@pharma.novartis.com
D000473:Alkanes / Q000138:chemical synthesis* / Q000494:pharmacology; D000477:Alkylating Agents; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D002219:Carbamates / Q000138:chemical synthesis* / Q000494:pharmacology; D018360:Crystallography, X-Ray; D006801:Humans; D007166:Immunosuppressive Agents / Q000138:chemical synthesis / Q000494:pharmacology; D007202:Indicators and Reagents; D007783:Lactones / Q000138:chemical synthesis* / Q000494:pharmacology; D009942:Organometallic Compounds / Q000737:chemistry; D011753:Pyrones
D000473:Alkanes; D000477:Alkylating Agents; D000970:Antineoplastic Agents; D002219:Carbamates; D007166:Immunosuppressive Agents; D007202:Indicators and Reagents; D007783:Lactones; D009942:Organometallic Compounds; D011753:Pyrones; C071229:discodermolide